About

Commercializing precise
& stable medical Cannabis products
for Better Therapeutic Effect

Leveraging the vast scientific know-how, intellectual property and the immense AI driven computational power of Evogene Ltd. (NASDAQ, TSE: EVGN), a global powerhouse in computational biology and plant innovation, Canonic uses predictive biology to breed genetically stable varieties for better therapeutic effects and higher yield. In Israel’s largest Cannabis R&D facility with state of the art greenhouse and molecular labs, Canonic focuses on developing Cannabis varieties that address three key industry pains: genetic stability, compound yield, and active compounds. Canonic caters to clients worldwide, bringing the gold standard in non-GMO, indication-specific Cannabis products.

Meet our team
Management
Dr. Arnon Heyman
CEO

Dr. Arnon Heyman is the CEO of Canonic Ltd. Dr. Heyman has previously served as VP and GM of Evogene’s Ag-Seeds division managing all plant genetics activities and related collaborations. Prior to Evogene, Dr. Heyman served as CTO of BondX Technologies Ltd. from 2009-2014.

Dr. Heyman holds a PhD. In Biotechnology from the Hebrew University in Jerusalem (2008) and a MBA from the College of Management (2015).

Dr. Inbal Dangoor
Head of R&D

Dr. Inbal Dangoor is an experienced plant scientist with expertise in genetics, biotechnology and computational biology. Prior to joining Canonic, Dr. Dangoor managed the New Breeding Technologies activities of Evogene and was the Corn research team leader in the Yield and Abiotic Stress division.

Dr. Dangoor holds a Ph.D. from the Weizmann Institute of Science in Rehovot (2010).

​

Ofer Haviv
Chairman of the board

Ofer Haviv holds the position of Evogene’s President and CEO as of late 2004. During his time at Evogene, he led two IPOs, in the Tel Aviv stock exchange (2008) and NYSE (2013). Additionally, during these years, Evogene had initiated several multi-year collaborations with world leading companies such as: Monsanto, BASF, Bayer, Corteva, Syngenta and ICL, to name a few.

Dorit Kreiner
CfO

Ms. Dorit Kreiner was appointed as CFO in February 2019, bringing over 20 years of senior financial management experience. She previously served as Chief Financial Officer in Therapix (TASE: THXBY) and NRGene. In addition, Ms. Kreiner served as Director of Finance of Evogene from June 2004 through August 2011.

Ms. Kreiner holds a BA in accounting and economics and an MBA in Finance and Marketing, both from Tel Aviv University, and a Bachelor of Law from the College of Management.

Board of Advisors
Dr. Yossi Tam
Cannabinoid clinical research
Director, Multidisciplinary Center for Cannabinoid Research of the Hebrew university
Dr. Yariv Brotman
Plant metabolic pathways
Ben Gurion University & Max Planck institute of Molecular Plant Physiology
Shai Leviatov
Plant breeding and product development
Commercial varieties breeding for more than 30 years in top leading multinational seeds companies.
We use cookies

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.